Research Summary

Dr. Chloe E. Atreya specializes in gastrointestinal cancer, particularly colorectal cancer, at the UCSF Helen Diller Comprehensive Cancer Center. She also co-directs the Integrative Onolcogy Program and Research Hub. Her research focuses on the interplay of tumor genetics and response to therapies for colorectal cancer, with the goal of improving patient outcomes and quality of life by personalizing treatment.

Research Funding

  • January 1, 2022 - December 21, 2026 - Understanding Intrinsic Resistance to Direct KRAS Inhibition In colorectal Cancers , Co-Investigator . Sponsor: NIH-NCI, Sponsor Award ID: R37CA266549
  • September 1, 2020 - August 1, 2025 - Optimization of a remote intervention to improve nutrition and physical activity in colorectal cancer survivors , Co-Investigator . Sponsor: NIH/NCI, Sponsor Award ID: R01CA248774
  • June 1, 2019 - May 31, 2024 - Kinome-guided Targeting of Cooperative Dependencies in BRAF and KRAS Mutated Colorectal Cancer , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA229447
  • June 21, 2018 - May 31, 2021 - (PQ10) Harnessing the human gut microbiome to predict chemotherapy outcomes , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: R21CA227232
  • September 15, 2013 - April 30, 2019 - Targeting of Aberrant Signaling in Patient-Derived Colorectal Cancer Models , Principal Investigator . Sponsor: NIH, Sponsor Award ID: K08CA175153

Education

Princeton University,  Princeton NJ, BA, 05/98, Molecular Biology,  Certificate in Visual Art
Yale University,  New Haven,  CT, PhD, 05/04, Pharmacology
Yale University,  New Haven,  CT, MD, 05/05, Medicine
University of Washington,  Seattle,  WA, 06/08, Internal Medicine,  internship and residency
University of California,  San Francisco, 06/10, Medical Oncology,  fellowship
University of California, San Francisco, 06/14, Certificate, Advanced Training in Clinical Research
University of California, San Francisco, 2018-2019, Clinical Fellowship in Integrative Medicine

Honors & Awards

  • 2011
    Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator Award
  • 2012
    UCSF Resource Allocation Program Spring 2012 Core Exploratory Award
  • 2012
    Alliance for Clinical Trials in Oncology Foundation Investigator Award
  • 2012
    Pilot Research Award for Junior Investigators, Mt. Zion Health Fund, Gump Cancer Fund from the Resource Evaluation and Allocation Committee, and HDFCCC
  • 2014
    The Ernest H. Rosenbaum MD Commitment to Patient Care Award, UCSF Symptom Management Service
  • 2017
    The Marcus Program in Precision Medicine Innovation Seeding Bold Ideas Award
  • 2017
    Inside Out Accelerator Award, UCSF Clinical Innovation Center
  • 2022
    Technologies, Methodologies & Cores Award, Sandler Program for Breakthrough Biomedical Research

Selected Publications

  1. Atreya CE, Leach H, Asiimwe E, Bahri N, Le BK, Macaire G, Wood KC, Van Blarigan EL, Lee RT. Integrative Oncology: Incorporating Evidence-Based Approaches for Patients With GI Cancers. Am Soc Clin Oncol Educ Book. 2025 Jan; 45(1):e471734.  View on PubMed
  2. Trepka KR, Kidder WA, Kyaw TS, Halsey T, Olson CA, Ortega EF, Noecker C, Upadhyay V, Stanfield D, Steiding P, Guthrie BGH, Spanogiannopoulos P, Dumlao D, Turnbaugh JA, Stachler MD, Van Blarigan EL, Venook AP, Atreya CE, Turnbaugh PJ. Expansion of a bacterial operon during cancer treatment ameliorates drug toxicity. bioRxiv. 2024 Oct 15.  View on PubMed
  3. Hillege LE, Trepka KR, Ziemons J, Aarnoutse R, Guthrie BGH, de Vos-Geelen J, Valkenburg-van Iersel L, van Hellemond IEG, Baars A, Vestjens JHMJ, Penders J, Deutschbauer A, Atreya CE, Kidder WA, Turnbaugh PJ, Smidt ML. Metagenomic analysis during capecitabine therapy reveals microbial chemoprotective mechanisms and predicts drug toxicity in colorectal cancer patients. medRxiv. 2024 Oct 15.  View on PubMed
  4. Silverstein J, Wright F, Stanfield D, Chien AJ, Wong JM, Park JW, Blanco A, Van Loon K, Atreya CE. Synchronous or metachronous breast and colorectal cancers in younger-than-average-age patients: a case series. Oncologist. 2024 Sep 06; 29(9):e1159-e1168.  View on PubMed
  5. Edwards AL, Trang K, Tolstykh IV, Van Blarigan EL, Van Loon K, Laffan A, Stanfield D, Steiding P, Neuhaus J, Atreya CE, Piawah S, Venook AP, Varma MG. Association between gastrointestinal symptoms and specialty care utilization among colon cancer survivors: a cohort study. Int J Colorectal Dis. 2024 Aug 14; 39(1):130.  View on PubMed
  6. Parikh AR, Chee BH, Tsai J, Rich TA, Price KS, Patel SA, Zhang L, Ibrahim F, Esquivel M, Van Seventer EE, Jarnagin JX, Raymond VM, Corvera CU, Hirose K, Nakakura EK, Corcoran RB, Van Loon K, Atreya CE. Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment. Clin Cancer Res. 2024 Jul 15; 30(14):2964-2973.  View on PubMed
  7. Mishra KK, Leung IC, Chao MT, Thompson-Lastad A, Pollak C, Dhruva A, Hartogensis W, Lister M, Cheng SW, Atreya CE. Mindfulness-Based Group Medical Visits: Strategies to Improve Equitable Access and Inclusion for Diverse Patients in Cancer Treatment. Glob Adv Integr Med Health. 2024 Jan-Dec; 13:27536130241263486.  View on PubMed
  8. Piawah S, Kyaw TS, Trepka K, Stewart AL, Mora RV, Stanfield D, Levine K, Van Blarigan EL, Venook A, Turnbaugh PJ, Nguyen T, Atreya CE. Associations between the Gut Microbiota, Race, and Ethnicity of Patients with Colorectal Cancer: A Pilot and Feasibility Study. Cancers (Basel). 2023 Sep 13; 15(18).  View on PubMed
  9. Carlson LE, Ismaila N, Addington EL, Asher GN, Atreya C, Balneaves LG, Bradt J, Fuller-Shavel N, Goodman J, Hoffman CJ, Huston A, Mehta A, Paller CJ, Richardson K, Seely D, Siwik CJ, Temel JS, Rowland JH. Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology-ASCO Guideline. J Clin Oncol. 2023 10 01; 41(28):4562-4591.  View on PubMed
  10. Kyaw TS, Upadhyay V, Tolstykh I, Van Loon K, Laffan A, Stanfield D, Gempis D, Kenfield SA, Chan JM, Piawah S, Atreya CE, Ng K, Venook A, Kidder W, Turnbaugh PJ, Van Blarigan EL. Variety of Fruit and Vegetables and Alcohol Intake are Associated with Gut Microbial Species and Gene Abundance in Colorectal Cancer Survivors. Am J Clin Nutr. 2023 09; 118(3):518-529.  View on PubMed
  11. Savoie MB, Paciorek A, Van Loon K, Anwar M, Atreya CE, Johnson PC, Kenfield SA, Laffan A, Levin AO, Smith JF, Stanfield D, Venook A, Zhang L, Van Blarigan EL, Rowen T. Sexual function remains persistently low in women after treatment for colorectal cancer and anal squamous cell carcinoma. J Sex Med. 2023 03 31; 20(4):439-446.  View on PubMed
  12. Wang L, Langlais C, Kenfield SA, Van Loon K, Laffan A, Atreya CE, Chan JM, Zhang L, Allen IE, Miaskowski C, Fukuoka Y, Meyerhardt JA, Venook AP, Van Blarigan EL. Quality of life among colorectal cancer survivors participating in a pilot randomized controlled trial of a web-based dietary intervention with text messages. Support Care Cancer. 2023 Feb 10; 31(3):155.  View on PubMed
  13. Ruiz-Saenz A, Atreya CE, Wang C, Pan B, Dreyer CA, Brunen D, Prahallad A, Muñoz DP, Ramms DJ, Burghi V, Spassov DS, Fewings E, Hwang YC, Cowdrey C, Moelders C, Schwarzer C, Wolf DM, Hann B, VandenBerg SR, Shokat K, Moasser MM, Bernards R, Gutkind JS, van 't Veer LJ, Coppé JP. A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors. Nat Cancer. 2023 02; 4(2):240-256.  View on PubMed
  14. Fidelman N, Atreya CE, Griffith M, Milloy MA, Carnevale J, Cinar P, Venook AP, Van Loon K. Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases. BMC Cancer. 2022 Dec 13; 22(1):1307.  View on PubMed
  15. Kenfield SA, Philip EJ, Phillips SM, Meyerhardt JA, Chan JM, Atreya CE, Kim MO, Harris Q, Steiding P, Macaire G, McCullough ML, Piawah S, Johnson WY, Kurttila FA, Lewis WL, Pesmen C, Watson Y, Van Blarigan EL. Optimizing intervention tools to improve nutrition and physical activity for colorectal cancer survivors (Tools To Be Fit): Study protocol of a randomized factorial experiment. Contemp Clin Trials. 2022 12; 123:107009.  View on PubMed
  16. Greenberg AL, Tolstykh IV, Van Loon K, Laffan A, Stanfield D, Steiding P, Kenfield SA, Chan JM, Atreya CE, Piawah S, Kidder W, Venook AP, Van Blarigan EL, Varma MG. Association between adherence to the American Cancer Society Nutrition and Physical Activity Guidelines and stool frequency among colon cancer survivors: a cohort study. J Cancer Surviv. 2023 06; 17(3):836-847.  View on PubMed
  17. Spanogiannopoulos P, Kyaw TS, Guthrie BGH, Bradley PH, Lee JV, Melamed J, Malig YNA, Lam KN, Gempis D, Sandy M, Kidder W, Van Blarigan EL, Atreya CE, Venook A, Gerona RR, Goga A, Pollard KS, Turnbaugh PJ. Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism. Nat Microbiol. 2022 10; 7(10):1605-1620.  View on PubMed
  18. Wang L, Langlais CS, Kenfield SA, Chan JM, Graff RE, Allen IE, Atreya CE, Van Blarigan EL. mHealth Interventions to Promote a Healthy Diet and Physical Activity among Cancer Survivors: A Systematic Review of Randomized Controlled Trials. Cancers (Basel). 2022 Aug 06; 14(15).  View on PubMed
  19. Piawah S, Walker EJ, Van Blarigan EL, Atreya CE. The Gut Microbiome in Colorectal Cancer. Hematol Oncol Clin North Am. 2022 06; 36(3):491-506.  View on PubMed
  20. Chan H, Van Loon K, Kenfield SA, Chan JM, Mitchell E, Zhang L, Paciorek A, Joseph G, Laffan A, Atreya C, Fukuoka Y, Miaskowski C, Meyerhardt JA, Venook AP, Van Blarigan EL. Quality of life of colorectal cancer survivors participating in a pilot randomized controlled trial of physical activity trackers and daily text messages. Support Care Cancer. 2022 May; 30(5):4557-4564.  View on PubMed

Go to UCSF Profiles, powered by CTSI